U.S. market Closed. Opens in 1 day 12 hours 16 minutes

PHAR | Pharming Group N.V. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for PHAR we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable.

Valuation (50%)

Company Industry
P/E Ratio (TTM) -33.72 -22.08
PEG Ratio (TTM) 0.96 15.66
P/S Ratio (TTM) 1.96 49.38
P/B Ratio (TTM) 2.60 18.85
P/FCF Ratio (TTM) -286.41 -3.07
Price to 5YR AVG Earnings Ratio 30.63 -3.42
Price to 5YR AVG FCF Ratio 154.64 -9.04

Profitability (5%)

Company Industry
ROA (TTM) -4.08% -5.15%
ROE (TTM) -8.08% 16.37%
Net Profit Margin (TTM) -6.07% -2,030.32%
ROIC 5YR AVG 4.72% 15.65%

Growth (23%)

4QTR AVG 3YR AVG 5YR AVG
EPS -110.27% -5.50% -23.30%
Revenue 6.36% 2.77% 5.37%
Net Income -107.74% -5.00% -44.82%
Cash Flow 50.89% -12.21% -42.61%

Health (56%)

Company Industry
Current Ratio (TTM) 3.53 6.19
Quick Ratio (TTM) 2.76 5.91
D/E Ratio (TTM) 0.44 -15.10
Interest Coverage (TTM) -2.12 -1.60
Piotroski F-Score 2 5
Altman Z-Score 1.94 14.02
LTL to 5YR AVG FCF 45.76 0.18
Shares Outstanding Growth 5YR AVG -21.31% 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙